Sights set on striking a balance between the benefits and risks

FDA update on labeling rules for long-acting opioid analgesics In April of this year, The U.S. Food and Drug Administration (FDA) has approved new safety-related changes for the class-wide labeling of extended-release and long-acting (ER/LA) opioid analgesics used for pain treatment.  In the fall of 2013, they also added new post-market study requirements for this […]

Sights set on striking a balance between the benefits and risks Read More »